Background The reversibility of new/novel oral anticoagulants (NOAC) is not well
understood, whereas the reversal strategies for bleeding associated with vitamin k …

The new oral anticoagulants/non-vitamin K antagonists oral anticoagulants (NOACs) have
recently reached the market and less is known about their safety in comparison to their …

Non-vitamin K antagonist oral anticoagulants (NOACs) are increasingly used in the
prevention and treatment of venous thromboembolism and in the prevention of stroke in …

Aims The objective was to compare major bleeding risk of direct oral anticoagulants
(DOACs; per type and dose) with vitamin K antagonists (VKAs), irrespective of indication …

Vitamin K antagonists are commonly used by clinicians to provide anticoagulation to
patients who have or are at risk of having thrombotic events. In addition to familiarity with the …

Modern direct-acting anticoagulants are rapidly replacing vitamin K antagonists (VKA) in the
management of millions of patients worldwide who require anticoagulation. These drugs …

Background & Aims Non–vitamin K antagonist oral anticoagulants (NOACs) are convenient
and effective in the prevention and treatment of venous thromboembolism and the …

Vitamin K antagonists (VKAs) have been the standard of care for treatment of
thromboembolic diseases. Target-specific oral anticoagulants (TSOACs) have been …

Background Oral anticoagulant therapy (VKA) is nowadays the mainstay of treatment in
primary and secondary stroke prevention in patients with atrial fibrillation. Given the limited …

The vitamin K antagonists (VKAs) are a widely used class of agent to prevent
thromboembolism. In recent years, numerous alternatives to VKAs have been developed …